Cardio Town Hall: Amyloidosis - What Are the New Therapeutic Options? Lessons Learned from ACC-Cardio Town Hall Amyloidosis - What Are the New Therapeutic Options? Lessons Learned from ACC

Cardio Town Hall Amyloidosis - What Are the New Therapeutic Options? Lessons Learned from ACC

Video Transcription

Video Summary

The discussion, led by Stephen Roblin and Dr. Ronald Voutelis, focuses on recent advancements and studies concerning ATTR amyloidosis, highlighting the rapid evolution in understanding and treating the disease. The panelists discussed the significant progress in recognition, diagnostic methods, and therapeutic options, particularly with RNAi-based therapies. The conversation focused on various studies showcasing the effectiveness of current and investigational therapies, like stabilizers and silencers, and explored their impact on outcomes like all-cause mortality and cardiac events. Among the therapies and diagnostics reviewed was a new next-generation RNA silencer, Nucrasiran, which offers promising once-every-six-month dosing. The panelists also considered the role of combination therapies and the importance of early disease detection using new diagnostic agents like ATO1. Both panelists emphasized the necessity for ongoing research, patient monitoring, and understanding the pathophysiology for future breakthroughs. They reflected on the exciting array of available and upcoming treatment modalities that enable better clinical decisions and potentially transform patient care in ATTR amyloidosis.

Keywords

ATTR amyloidosis

RNAi-based therapies

Nucrasiran

diagnostic methods

combination therapies

early detection

therapeutic options